{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:59:54Z","timestamp":1777672794749,"version":"3.51.4"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00400","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T14:37:52Z","timestamp":1585319872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective"],"prefix":"10.3389","volume":"10","author":[{"given":"Ashok K.","family":"Vaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh C.","family":"Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shona","family":"Nag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanchal","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14656566.2013.776541","article-title":"Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients","volume":"14","author":"Janelsins","year":"2013","journal-title":"Expert Opin Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0885-3924(00)00249-9","article-title":"The changeable nature of patients' fears regarding chemotherapy: implications for palliative care","volume":"21","author":"Passik","year":"2001","journal-title":"J Pain Symptom Manage."},{"key":"B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1523-5394.1999.07205.x","article-title":"Perception of chemotherapy side effects cancer versus noncancer patients","volume":"7","author":"Lindley","year":"1999","journal-title":"Cancer Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics perception versus reality","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0277-5379(83)90418-2","article-title":"On the receiving end\u2013patient perception of the side-effects of cancer chemotherapy","volume":"19","author":"Coates","year":"1983","journal-title":"Eur J Cancer Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","article-title":"Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support Care Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a010548","article-title":"On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993","volume":"7","author":"Griffin","year":"1996","journal-title":"Ann Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.2165\/11203680-000000000-00000","article-title":"Aprepitant: a review of its use in the prevention of nausea and vomiting","volume":"69","author":"Curran","year":"2009","journal-title":"Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"212285","DOI":"10.7573\/dic.212285","article-title":"An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries","volume":"4","author":"Turini","year":"2015","journal-title":"Drugs Context."},{"key":"B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.18553\/jmcp.2012.18.5.385","article-title":"Assessment of the relationship between adherence with antiemetic","volume":"18","author":"Chan A Low","year":"2012","journal-title":"J Manag Care Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/IGC.0b013e318234f9ee","article-title":"Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer","volume":"22","author":"Perwitasari","year":"2012","journal-title":"Int J Gynecol Cancer."},{"key":"B14","unstructured":"Negative impact of chemotherapy on breast cancer patients QOL - Utility of antiemetic treatment guidelines and the role of race152327\n            Abdul BHassan\n            BintiZ\n          Asian Pac J Cancer Prev.112010"},{"key":"B15","first-page":"296","article-title":"Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: Survey of five Canadian centres","volume":"149","author":"Brien","year":"1993","journal-title":"CMAJ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00520-005-0803-x","article-title":"Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials","volume":"13","author":"Neymark","year":"2005","journal-title":"Support Care Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B18","first-page":"5","article-title":"Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches","volume":"8","author":"Frame","year":"2010","journal-title":"J Support Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1200\/JGO.2016.006023","article-title":"Survey of implementation of antiemetic prescription standards in Indian oncology practices and its adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline","volume":"3","author":"Patil","year":"2017","journal-title":"J Glob Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.4143\/crt.2015.309","article-title":"Clinical practices and outcomes on chemotherapy-induced nausea and vomiting management in South Korea: comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study","volume":"48","author":"Lee","year":"2016","journal-title":"Cancer Res Treat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American college of chest physicians task force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest."},{"key":"B22","unstructured":"NCCN Guidelines Antiemesis2018"},{"key":"B23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s005200050161","article-title":"Anticipatory nausea and vomiting in the era of 5-HT 3 antiemetics","volume":"6","author":"Morrow","year":"1998","journal-title":"Support Care Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/00000421-199106000-00010","article-title":"Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized, single-blind study","volume":"14","author":"Roila","year":"1991","journal-title":"Am J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2165\/00003495-199855020-00002","article-title":"5-HT 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy","volume":"55","author":"Gregory","year":"1998","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","article-title":"Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model","volume":"64","author":"Pollera","year":"1989","journal-title":"Cancer."},{"key":"B27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines : results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJM198309293091316","article-title":"Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion","volume":"309","author":"Sullivan","year":"1983","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy : analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support Care Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00520-010-0982-y","article-title":"Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients : a prospective, longitudinal, observational study","volume":"19","author":"Pirri","year":"2011","journal-title":"Support Care Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00520-001-0321-4","article-title":"Pretreatment factors predicting the development of post chemotherapy nausea and vomiting in Chinese breast cancer patients","volume":"10","author":"Molassiotis","year":"2002","journal-title":"Support Care Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment:analysis of phase 3 trial of aprepitant in patients receiving adriamycin - cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support Care Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpainsymman.2006.11.014","article-title":"The effects of family support, anxiety, and post-treatment nausea on the development of anticipatory nausea : a latent growth model","volume":"34","author":"Kim","year":"2007","journal-title":"J Pain Symptom Manage."},{"key":"B35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jpainsymman.2015.12.317","article-title":"Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting : results from the Pan European Emesis Registry Study","volume":"51","author":"Molassiotis","year":"2016","journal-title":"J Pain Symptom Manage."},{"key":"B36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/PSY.0000000000000372","article-title":"Longitudinal association of poor sleep quality with chemotherapy-induced nausea and vomiting in patients with breast cancer","volume":"78","author":"Jung","year":"2016","journal-title":"Psychosom Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2147\/CMAR.S176574","article-title":"Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy : a prospective, observational, multicenter study","volume":"10","author":"Matsuo","year":"2018","journal-title":"Cancer Manag Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1634\/theoncologist.9-1-80","article-title":"Complementary and alternative therapies for cancer","volume":"9","author":"Cassileth","year":"2004","journal-title":"Oncologist."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00520-014-2175-6","article-title":"Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Popovic","year":"2014","journal-title":"Support Care Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"17","author":"Aapro","year":"2006","journal-title":"Ann Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT 3 results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1517\/14656566.4.12.2297","article-title":"Palonosetron-a unique 5-HT 3 -receptor antagonist for the prevention of chemotherapy-induced emesis","volume":"4","author":"Grunberg","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"B43","first-page":"871","article-title":"Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer","volume":"51","author":"Kaushal","year":"2010","journal-title":"Singapore Med J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy : a double-blind, double-dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1007\/s00520-016-3304-1","article-title":"Efficacy benefit of an NK 1 receptor antagonist (NK 1 RA) in patients receiving carboplatin : supportive evidence with NEPA (a fixed combination of the NK 1 RA, netupitant, and palonosetron) and aprepitant regimens","volume":"24","author":"Jordan","year":"2016","journal-title":"Support Care Cancer."},{"key":"B46","doi-asserted-by":"publisher","first-page":"FC10","DOI":"10.7860\/JCDR\/2017\/25129.9818","article-title":"Comparison of antiemetic effectiveness of palonosetron versus ondansetron in patients on cancer chemotherapy: a prospective observational Study in South Indians","volume":"11","author":"Parathoduvil","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.12788\/jcso.0139","article-title":"Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children","volume":"13","author":"Patil","year":"2015","journal-title":"J Community Support Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-015-0379-3","article-title":"Comparative safety of serotonin (5-HT 3) receptor antagonists in patients undergoing surgery : a systematic review and network meta-analysis","volume":"13","author":"Tricco","year":"2015","journal-title":"BMC Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","article-title":"Academy of Geriatric Cancer Research (AgeCare). 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects","volume":"13","author":"Brygger","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"B50","unstructured":"FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran).2012"},{"key":"B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00520-003-0528-7","article-title":"Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis","volume":"12","author":"Villalon","year":"2004","journal-title":"Support Care Cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdl347","article-title":"Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis","volume":"18","author":"Grunberg","year":"2007","journal-title":"Ann Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jhmhp.2018.04.05","article-title":"Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Chow","year":"2018","journal-title":"JHMHP."},{"key":"B54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients","volume":"9","author":"Kaushal","year":"2015","journal-title":"Ecancermedicalscience."},{"key":"B55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/2278-330X.149923","article-title":"Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy\/moderately emetogenic chemotherapy regimens","volume":"4","author":"Hingmire","year":"2015","journal-title":"South Asian J Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4103\/0019-509X.123580","article-title":"A Phase 3, randomized, double blind study of single dose fosaprepitant for prevention of cisplatin induced nausea and vomiting : results of an Indian population sub analysis","volume":"50","author":"Maru","year":"2013","journal-title":"Indian J Cancer."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e27551","DOI":"10.1002\/pbc.27551","article-title":"Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial","volume":"66","author":"Radhakrishnan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/JCO.JCO_2_19","article-title":"A retrospective case cohort analysis on the clinical utility of fosaprepitant for CINV prophylaxis in day care center of South India","volume":"2","author":"Ramesh","year":"2019","journal-title":"J Curr Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.2147\/OTT.S158570","article-title":"Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting","volume":"11","author":"Navari R Schwartzberg","year":"2018","journal-title":"Onco Targets Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.7314\/APJCP.2016.17.4.1661","article-title":"Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Yuan","year":"2016","journal-title":"Asian Pac J Cancer Prev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO.2013.51.4547","article-title":"Aprepitant versus dexamethasone for prevention chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind Study","volume":"32","author":"Roila","year":"2014","journal-title":"J Clin Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? - a systematic review and meta-analysis","volume":"26","author":"Jordan","year":"2018","journal-title":"Support Care Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1634\/theoncologist.2017-0378","article-title":"Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy- induced nausea and vomiting associated with highly emetogenic chemotherapy : a network meta-analysis","volume":"23","author":"Zhang","year":"2018","journal-title":"Oncologist."},{"key":"B64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00520-016-3386-9","article-title":"Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients : a randomized controlled study","volume":"25","author":"Mukhopadhyay","year":"2017","journal-title":"Support Care Cancer."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3439707","DOI":"10.1155\/2016\/3439707","article-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a Pilot Study from South India","volume":"2016","author":"Babu","year":"2016","journal-title":"Chemother Res Pract."},{"key":"B66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12032-017-1074-3","article-title":"Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy","volume":"35","author":"Mehra","year":"2017","journal-title":"Med Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/ijp.IJP_846_16","article-title":"Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study","volume":"49","author":"Shivaprakash","year":"2017","journal-title":"Indian J Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment : agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2017","journal-title":"Support Care Cancer."},{"key":"B70","doi-asserted-by":"publisher","first-page":"943618","DOI":"10.1155\/2015\/943618","article-title":"Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy","volume":"2015","author":"Ranganath","year":"2015","journal-title":"Biomed Res Int."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","article-title":"Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy","volume":"21","author":"Olver","year":"2013","journal-title":"Support Care Cancer."},{"key":"B72","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s00520-010-0920-z","article-title":"Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant : review and consensus statement","volume":"19","author":"Einhorn","year":"2011","journal-title":"Support Care Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00520-007-0255-6","article-title":"Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer","volume":"15","author":"Einhorn","year":"2007","journal-title":"Support Care Cancer."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T14:37:56Z","timestamp":1585319876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":73,"alternative-id":["10.3389\/fonc.2020.00400"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00400","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]},"article-number":"400"}}